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Introduction: Hepatitis C virus (HCV) infection can be detected in virtually all patients with cryoglobulinemic
vasculitis (CV). Among its many effects, the virus is able to stimulate the production of thymic stromal lymphopoietin
(TSLP) by infected hepatocytes. In this study, we assessed the systemic levels and tissue distribution of TSLP in 60
chronically HCV-infected patients, 36 with and 24 without CV.
Methods: Serum TSLP levels were measured by an enzyme-linked immunosorbent assay (ELISA) method. TSLP mRNA
was assessed in patient samples by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). TSLP protein in liver
and skin biopsy samples was revealed by indirect immunofluorescence. All other methods were carried out according to
standardized procedures.
Results: Serum TSLP levels were significantly higher in patients with than in those without CV and in healthy individuals.
Higher TSLP levels paralleled specific mRNA expression and the up-regulation of TSLP protein in liver tissue. Compared
with non-CV patients, higher TSLP levels in CV were accompanied by a higher frequency of circulating mono/oligoclonal
B-cell expansions (8% vs. 92%, p < 0.0001) and a higher number of peripheral CD20+ B-cells (10.3% vs. 15.5% p = 0.04).
In addition, TSLP mRNA expression in the liver of CV patients was lower than in their correspondent skin tissue and
paralleled specific immune deposits of TSLP protein in keratinocytes.
Conclusion: Overall, this study shows that TSLP secreted by hepatocytes and keratinocytes of HCV-infected
patients with CV is involved in the pathogenesis of vasculitis and may possibly support the therapeutic use of
TSLP-targeted monoclonal antibodies.Introduction
Thymic stromal lymphopoietin (TSLP) is a four-helix-
bundle cytokine and a member of the common γ-chain
cytokines, which are able to induce dendritic cells (DCs)
and to stimulate naïve T-cell differentiation into T-helper
2 [1] and T-helper 17 [2] cells. TSLP binding and signaling
occur by means of a heterodimer composed of the
interleukin-7 receptor α-chain and the TSLP receptor [3].
TSLP is a potent modulator of systemic B-cell devel-
opment and is capable of promoting humoral auto-
immunity. In the skin of a genetically engineered
mouse, TSLP released into the systemic circulation by
Notch-deficient keratinocytes induced a remarkable* Correspondence: domenicoettore.sansonno@uniba.it
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unless otherwise stated.expansion of peripheral pre-B cells and immature B
lymphocytes, resulting in B-lymphoproliferative disor-
ders and death [4]. In addition, local expression of
TSLP under the control of a tetracycline-regulated,
skin-specific promoter caused a substantial increase in
bone marrow B lymphocytes and an earlier exodus of
immature cells to the periphery [5]. These changes
led to an increase in antibody-secreting cells, the pro-
duction of mixed cryoglobulins, immune-complex-
mediated renal damage [6], and systemic inflammatory
injury, an overall picture closely resembling human
cryoglobulinemic vasculitis (CV) [7].
In the Mediterranean basin, over 90% of CV patients are
chronically infected with hepatitis C virus (HCV), thus
emphasizing the role of this virus in the pathogenesis of
cryoglobulin production. However, only a subset of HCV-
positive individuals develops mixed cryoglobulins and onlyral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cell clonal expansions in the circulation and in the liver
microenvironment are peculiar features of the humoral
immune response of CV patients [9]. In addition, domin-
ant B-cell clonalities probably contribute to the forma-
tion of intraportal follicle-like structures in the liver
[10]. Analysis of the immunoglobulin heavy chain
complementarity-determining region CDR-3, whether
from circulating or tissue-derived B-cell-expanded
clones, showed several variations in this immuno-
globulin gene segment, supporting the notion that
these cells are the result of an antigen-driven response
[11]. Restriction in the use of the B-cell V gene was
shown to have a direct clinical impact in CV patients,
based on its association with higher levels of rheuma-
toid factor activity and with lymphoproliferative disor-
ders [12,13].
Recently, it has been reported that the infection of
hepatocytes in vitro by HCV results in a remarkable
production of TSLP [14] through a mechanism regu-
lated in a nuclear factor-κB-dependent fashion, and
that TSLP is able to enhance the release of T-helper
17 differentiating cytokines by DCs. In view of
this finding, it can be argued that upregulation of
hepatocyte-derived TSLP plays a major role in the loss
of B-cell tolerance, resulting in the drastic expansion
of B-cell populations and the stimulation of cryo-
globulin production in chronically HCV-infected pa-
tients. Since TSLP is required for the initial expansion
of B1 and B2 bone marrow B-cell progenitors [15], it
can also be postulated that an increase in systemic
TSLP levels in HCV-infected patients enhances B-cell
lymphopoiesis and the expansion of specific B-cell
subsets, leading to override of some of the controls
underlying B-cell tolerance.
Here, we asked whether an in vivo inducible upregu-
lation of TSLP can be shown in patients with chronic
HCV infection and CV. A possible relationship be-
tween TSLP and HCV nucleocapsid core protein,
devoid of envelope proteins, as a constitutive compo-
nent of cryoglobulins and potentially able to cause
cryoglobulin-mediated tissue injury [16] was also in-
vestigated. Our data indicate that high serum levels of
TSLP parallel those of specific mRNA transcripts,
both in the liver and to a higher extent in the skin of
HCV-infected patients, suggesting that this cytokine




Thirty-six naïve patients with a diagnosis of CV and
the classical symptom triad of palpable purpura, arth-
ralgia, and asthenia were enrolled in this study.Eligibility criteria were as follows: no previous therapy
with interferon, steroids, or immunosuppressive drugs;
serum positivity for anti-HCV antibodies and HCV
RNA; liver histology compatible with chronic active
hepatitis; negativity for serum HBsAg and anti-HIV anti-
bodies; alcohol intake <40 g/day; and currently not preg-
nant. The study was approved by the Independent Ethical
Committee (Azienda Ospedaliero-Universitaria ‘Policlinico
Consorziale’, Bari, Italy); written, informed consent was ob-
tained from all patients, in accordance with the declaration
of Helsinki.
Serum cryoglobulins were isolated and characterized
as described elsewhere [17]. In addition to diagnostic
liver biopsy, all HCV-infected patients underwent two
3 mm punch biopsies from two cutaneous lesions.
Control skin samples were derived from 24 chronically
HCV-infected patients (16 males, mean age: 55.2 ±
14.9 years) who tested negative for mixed cryoglobuline-
mia on three or more occasions and from 10 healthy
subjects (six males, mean age: 48 ± 9.4 years), all of them
undergoing surgical procedures because of inguinal or
abdominal hernias, subcutaneous nodules, cutaneous
squamous cell carcinoma, saphenectomy, or nodal nevi.
Liver and skin biopsy specimens were either formalin-
fixed and paraffin-embedded for routine histological
examination or embedded at the optimal cutting
temperature, snap frozen, and stored at −80°C until sec-
tioning for use in immunofluorescence studies. Portions
of the biopsy samples were prepared for molecular ana-
lyses. The specimens were placed in RNase-free micro-
tubes and immediately frozen in liquid nitrogen until
RNA extraction.
Patients were treated with pegylated interferon alpha/
ribavirin (pIFNα/RBV) combination therapy. Those in-
fected with genotype 2 and genotype 3 were treated for
6 months, and those infected with genotype 1 for
12 months. Patients were reassessed 6 months after dis-
continuation of therapy to establish whether they had
achieved a sustained virological response.
Virological, epidemiological, histological, and labora-
tory features as well as major symptomatology are sum-
marized in Table 1.
Laboratory parameters
Serum HCV antibodies were detected by second-
generation enzyme-linked immunosorbent assay and
then confirmed by third-generation enzyme-linked im-
munosorbent assay (Abbott Lab, Chicago, IL, USA) in
the first 18 patients enrolled in this study. The last
method was consistently employed in the remaining
42 patients. Serum HCV RNA was determined by RT-
PCR (Roche Diagnostics, Branchburg, NJ, USA) and
quantified with the Versant HCV RNA quantitative 3.0
assay (Siemens Healthcare, Erlangen, Germany). HCV
Table 1 Virological, epidemiological, histological, laboratory, and clinical characteristics of chronically HCV-infected
patients with and without cryoglobulinemic vasculitis
With CV (n = 36) Without CV (n = 24) P valuea
Virology
Serum HCV RNA 36 (100) 24 (100)
• Titer (log IU/ml) 5.9 (4.3 to 6.9) 6.2 (5.9 to 6.7) NS
Serum HCV core protein 36 (100) 24 (100)
• Titer (pg/ml) 15 (0.8 to 130) 46 (0.2 to 385) 0.08
HCV genotype
• Genotype 1 21 (58) 14 (58) NS
• Genotype 2 15 (42) 8 (33) NS
• Genotype 3 0 2 (9) NS
Anti-HCV antibodies 36 (100) 24 (100)
HBsAg 0 0
Anti-HIV antibodies 0 0
Epidemiology
Sex: male/female (ratio) 9/27 (0.33) 16/8 (2) 0.003
Age (years) 58.3 ± 9.5 55.2 ± 14.9 NS
Blood/blood product transfusion 12 (33) 9 (37.5) NS
Liver histology (METAVIR scoring system)
F0 2 (5.6) 0 NS
F1 6 (16.7) 4 (16.7) NS
F2 11 (30.5) 9 (37.5) NS
F3 8 (22.2) 4 (16.7) NS
F4 9 (25) 7 (29.1) NS
Laboratory




RF (IU/ml, ≤20) 101 (2 to 2,950) 12 (2 to 28) <0.0001
Immunoglobulins
IgM (mg/dl, 40 to 230) 294 (73 to 1,050) 142 (28 to 201) <0.0001
Complement fractions
C1q (mg/dl, 21 to 39) 37 (34 to 75) 28 (23 to 46) NS
C3 (mg/dl, 90 to 180) 102 (44 to 167) 101 (85 to 109) NS
C4 (mg/dl, 10 to 40) 2.5 (1 to 19) 14 (9 to 20) <0.0001
ALT (IU/l, ≤30) 59.5 (33 to 124) 83 (63 to 231) NS
Peripheral lymphocytogram
CD20 (%, 10.2 ± 5.4) 15.5 (5.5 to 81) 10.3 (7 to 25) 0.04
Circulating B-cell clonalities
Monoclonal 21 (58.4) 0 <0.0001
Oligoclonal 12 (33.3) 2 (8.3) 0.03
Polyclonal 3 (8.3) 22 (91.7) <0.0001
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Table 1 Virological, epidemiological, histological, laboratory, and clinical characteristics of chronically HCV-infected
patients with and without cryoglobulinemic vasculitis (Continued)
Clinical features
Palpable purpura 27 (75) 0
Weakness 24 (66.7) 4 (16.7)
Arthralgias/nonerosive arthritis 27 (75) 3 (12.5)
Cutaneous ulcers 21 (58.3) 1 (4.2)
Peripheral neuropathies 18 (50) 0
Renal disease 9 (25) 0
Data presented as n (%), median (range) or mean ± standard deviation. CV, cryoglobulinemic vasculitis; HCV, hepatitis C virus; NS, not significant; RF, rheumatoid
factor. aP <0.05 was defined as significant.
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NV, Ghent, Belgium).
Soluble thymic stromal lymphopoietin
Immunoreactive TSLP in serum samples was quanti-
fied using an enzyme-linked immunosorbent assay
with matched antibodies, according to the basic la-
boratory protocol provided by the manufacturer (R&D
Systems, Minneapolis, MN, USA). TSLP protein was
quantified with reference to serial dilutions of the re-
combinant standards, falling within the linear part of
the standard curve for each specific TSLP value mea-
sured. The sensitivity threshold of the TSLP assay is
6.7 pg/ml. Each data point represents readings from
two independent assays performed in duplicate.
Circulating hepatitis C virus core protein
Serum nonenveloped HCV core protein was tested
using Architect HCV Ag (Abbott Diagnostics, Wiesbaden,
Germany), a fully automated, quantitative, chemilu-
minescent microparticle immunoassay for the detec-
tion of nonenveloped HCV core protein in HCV-infected
sera [16].
Tissue RNA isolation and PCR amplification
Total RNA was extracted from liver and skin samples
with the RNeasy Mini kit (Qiagen, Hilden, Germany),
according to the manufacturer’s protocol, and reverse
transcribed to cDNA using the iScript Select cDNA
synthesis kit (Bio-Rad Laboratories, Hercules, CA,
USA). Five microliters of cDNA were used in a nested
PCR for HCV RNA detection together with the
AmpliTaq Gold PCR master mix (Applied Biosystems,
Foster City, CA, USA) and the following primer
sets targeting the 5′-untranslated region: sense 5′-
GGGGGCGACACTCCACCA-3′ (position 15 to 32)
and anti-sense 5′-TCGCGACCCAACACTACTC-3′
(position 256 to 274) for the first round of amplifica-
tion; and the inner primers sense 5′-GAGTGTCGTG
CAGCCTCCAG-3′ (position 98 to 117) and anti-sense 5′-CTCGGCTAGCAGTCTCGCGG-3′ (position
239 to 258) for the second round.
An additional PCR for TSLP mRNA was carried out
using 5 μl cDNA, the AmpliTaq Gold PCR master mix
(Applied Biosystems), and the QuantiTect human TSLP
primer assay (Qiagen). This primer set targets exons
1/2/3 and amplifies a region of 94 base pairs in the
two transcripts (2,629 base pairs and 3,834 base pairs,
respectively).
Real-time RT-PCR for TSLP mRNA quantification
TSLP mRNA was measured in patient samples by absolute
real-time RT-PCR quantification. The reaction was per-
formed using the QuantiTect human TSLP primer assay
(Qiagen) and FastStart DNA Master SYBR Green I (Roche
Diagnostics, Mannheim, Germany) on a LightCycler 1.5 in-
strument (Roche Diagnostics), according to the manufac-
turer’s protocol. The cycling conditions were 95°C for
15 minutes, 45 cycles of 94°C for 15 seconds, 55°C for
20 seconds, and 72°C for 20 seconds. The final concentra-
tion of TSLP mRNA was expressed as copies of mRNA per
nanogram of total RNA.
Real-time RT-PCR for HCV RNA quantitation was
performed using the RNA Master HybProbe kit (Roche
Diagnostics) and the following primers and probes: 5′-A
GCGTCTAGCCATGGCGT (sense), 5′-CAAGCACCCT
ATCAGGCAGT (antisense), 5′-LC640-CCCGGGAGAG
CCATAGTGGTCTG–PH (5′LCRed640) and 5′-GCA
GCCTCCAGGACCCCCC–FL (3′HCV-G-Fitch) (TIB
MOLBIOL, Berlin, Germany). To generate a standard
curve, serial dilutions of the AcroMetrix HCV Mid
Control (AcroMetrix, Benicia, CA, USA) were pre-
pared. The HCV RNA concentration was calculated as
International Units per nanogram of total RNA; the
sensitivity was 20 IU. Each sample and standard curve
point was run in duplicate.
Construction of standards for real-time RT-PCR absolute
quantification
The TSLP standard was constructed by cloning product
of real-time RT-PCR obtained using a bioinformatically
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gen). The PCR product was visualized on a 2% agarose
gel and the respective band was excised and loaded
onto a DNA purification column (DNA gel extraction
kit; Millipore, Billerica, MA, USA). The purified PCR
product was cloned into a pGEM-T Easy vector using
pGEM-T Easy vector system II (Promega, Madison,
WI, USA), according to the manufacturer’s protocol.
The recombinant vector was transformed into JM109
Escherichia coli competent cells (Promega). The trans-
formants were plated onto duplicate LB/ampicillin/
IPTG/X-Gal plates, incubated overnight at 37°C, and
then selected and processed for plasmid isolation. Five
milliliters of Luria-Bertani broth cultures of single colonies
were grown overnight at 37°C with shaking at 200 rpm.
The DNA plasmid was purified using the QIAprep spin
miniprep kit (Qiagen) and then solubilized in 100 μl
of 10 mM Tris–HCl (pH 8.5) buffer. To confirm the
sequence of the cloned product, DNA sequencing was
performed using the BigDye Terminator v1.1 cycle se-
quencing kit and ABI Prism 310 genetic analyzer (both
Applied Biosystems). The purified plasmid was quantified
and the copy number calculated as follows:
Number of copies=μl
¼ 6:023 10
23 molecules=moleð Þ  pDNA concetration g=μlð Þ
pGEMT‐T lengthþ TSLP length½  bpð Þ  660 g=moleð Þ
6:023 1023 molecules=mole ¼ Avogadro0s numberð Þ
660 g=moleð Þ ¼ Average weight of a single base pair
where 6,023 × 1023 (molecules/mole) is Avogadro’s
number and 660 (g/mole) is the average weight of a sin-
gle base pair. The standard curve was prepared from
five-point serial 10-fold dilutions, starting from 300,000
copies.
Thymic stromal lymphopoietin protein detection
TSLP protein in liver and skin biopsy samples was detected
by indirect immunofluorescence, using a goat anti-human
TSLP antibody (Biorbyrt, Cambridge, UK) at a working
concentration of 10 μg/ml. As a positive control, human
tonsil sections were employed. The samples were incubated
with the primary antibody for 3 hours at room temperature.
Isotype-matched antibodies were used for control staining
and a fluorescein isothiocyanate-conjugated rabbit anti-goat
antibody F(ab)2 fragment (Dako Denmark, Glostrup,
Denmark) as the secondary reagent. The latter was incu-
bated with the samples for 2 hours at room temperature.
To block a positive reaction on selected samples, the pri-
mary antibody was preincubated with human recombinant
TSLP protein (5 ng/ml).
Hepatitis C virus core protein detection
A two-stage indirect immunofluorescence procedure
was carried out as described previously [18], using anantibody (clone 4,6 E7-F6) that recognizes amino acids
29 to 43 (working concentration 0.9 pg/ml).
B-cell clonal expansions
The immunoglobulin heavy chain variable-diversity-
joining gene segments were amplified in duplicate reac-
tions according to the Fr3 protocol, as described else-
where [9,10]. Consensus primers for the V and J regions
were: an upstream primer complementary to the third
framework V region, 5′-ACACGGC(C/T)(C/G)TGTAT-
TACTGT-3′; and a downstream primer directed to a
conserved sequence of the J region, 5′-TGAGGA-
GACGGTGACC-3′, and in the second-round amplifica-
tion of an inner conserved sequence of the same J
region, 5′-GTGACCAGGGTNCCTTGGCCCCAG-3′.
Statistical analysis
Descriptive statistics included the mean or median as
appropriate for continuous variables, and the fre-
quency (%) for categorical variables. In the univariate
analysis, chi-square and Fisher’s exact tests were used
as appropriate to compare categorical variables, and
the nonparametric Mann–Whitney test to compare
continuous variables. The differences were considered
significant at P <0.05. A Spearman rank correlation
coefficient (r) test was used to evaluate the relation-
ships between variables. All statistical analyses were




As shown in Table 1, all CV patients were anti-HCV-
positive, viremic, and had circulating nonenveloped
HCV core protein. Except for a moderate prevalence of
genotype 1, no distinct distribution profile emerged
among the patients. Liver damage was histologically de-
fined. Laboratory parameters indicated normal serum
levels of complement components C1q and C3, but re-
markably low serum levels of C4. Molecular analyses
aimed at determining immunoglobulin heavy chain
variable-diversity-joining gene rearrangements showed
that B-cell clonalities were expanded in 33 (92%) CV
patients and in only two (8%) non-CV patients (P <0.0001).
The mean percentage of CD20+ B cells was higher in CV
than in non-CV patients (P = 0.04).
There was a strikingly higher number of female pa-
tients with mixed cryoglobulinemia (27 out of 36, 75%).
This reflects the higher female prevalence in all major
cohorts of CV – including our own series of 141 pa-
tients, 68% of whom were females [19]. However, serum
TSLP levels were not significantly different between
sexes in each group of patients.
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purpura, asthenia, and arthralgia/arthritis were recorded
with high frequency. Peri-malleolar and/or pre-tibial cu-
taneous ulcers were also found in over one-half of the
patients. Long-lasting hyperpigmentation affecting the
legs to a variable extent, as the result of recurrent pur-
puric eruptions, was also almost invariably present. Skin
histology showed leukocytoclastic vasculitis in 32 pa-
tients (89%), whereas pandermal vasculitis characterized
by vessel thrombosis and severe endothelial alterations
was diagnosed in the remaining four patients (11%).
Sensory-motor peripheral neuropathy was demonstrated
in one-half of the patients, in whom electromyography
prevalently revealed symmetrical, distal polyneuropathy
and, less frequently, mononeuritis multiplex. Renal damage
was diagnosed in 25% of the patients, with renal biopsy
showing membrano-proliferative glomerulonephritis in
78% and membranous nephropathy with segmental glo-
merulosclerosis in the remaining 22%.
In situ TSLP and HCV core protein immune detection
TSLP-specific immune reactive material was demon-
strated in 31 of 36 (86%) and 19 of 24 (79%) liver tissue
specimens from CV and non-CV patients, respectively.
As shown in Figure 1, although TSLP was detected in
the cytoplasm of hepatocytes, the number of stainable
liver cells varied greatly among liver specimens: TSLPFigure 1 Representative features of thymic stromal lymphopoietin im
cryoglobulinemic vasculitis. Specific fluorescent staining is seen in the cy
nuclear staining is demonstrable. Thymic stromal lymphopoietin (TSLP) imm
and in biliary epithelium (D, E). The fluorescence signal is completely aboli
FITC, fluorescein isothiocyanate.was in fact randomly distributed throughout the liver
sections but without an obvious topographical relation-
ship to liver structures. No distinct nuclear staining
pattern was noted. Positivity of cell membranes or sub-
membranes was infrequent (Figure 1A,B). In addition,
TSLP immune deposits were detected in portal tracts
containing inflammatory infiltrates (Figure 1C) and in
biliary epithelium (Figure 1D,E).
TSLP and HCV core proteins were studied in skin bi-
opsy samples from all CV and non-CV patients and
from healthy controls. The results showed that TSLP
protein was mostly restricted to the basal and suprabasal
layers of the epidermis (Figure 2A,B,C) in the large ma-
jority of both CV patients (27/31, 87%) and non-CV pa-
tients (15/19, 79%). No peculiar features were detected
in the remaining TSLP distribution patterns. Analysis of
the dermal layer showed TSLP protein deposition mainly
in blood vessel walls (Figure 2D). Similarly, HCV core
protein could be demonstrated within and/or around
dermal vessels. Intravascular core reactivity appeared as
coarse deposits completely filling the vessel lumen or as
immune reactants within vessel walls and in the perivas-
cular area (Figure 2G,H,I,J). Attempts to detect deposits
of HCV-encoded core protein in keratinocytes consist-
ently met with failure. None of the skin biopsy tissues
from non-CV patients or healthy individuals were posi-
tive for TSLP or HCV core protein.munodetection in liver biopsy specimens from patients with
toplasm of hepatocytes (A), and especially in perinuclear areas (B). No
unostaining is detected in inflammatory infiltrates of portal tracts (C)
shed by preincubation of the anti-TSLP antibody with TSLP protein (F).
Figure 2 Detection of thymic stromal lymphopoietin and hepatitis C virus core proteins in the skin biopsies of cryoglobulinemic
vasculitis patients by indirect immunofluorescence. Thymic stromal lymphopoietin (TSLP) immunoreactivity is present in the epidermis (A),
both in basal (B) and suprabasal (C) layers. In the dermis, TSLP immune reactants are localized in the vessel walls (D). There is no TSLP signal in
the skin of normal subjects (E). Intense signal of TSLP-specific immune reactants in human tonsil section as positive control (F). Hepatitis C virus
(HCV) core protein immune deposits are found only in the dermis, whereas keratinocytes never displayed positivity (G). Intravascular HCV core
immunostaining completely fills the vessel lumen (H, I) or is localized perivascularly (J). FITC, fluorescein isothiocyanate.
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amplicons in the skin
Notably, although TSLP mRNA expression was demon-
strated in the skin samples of CV and non-CV patients
and in those of healthy controls, HCV RNA amplifica-
tion products were present in only two (6%) of 36 skinTable 2 Thymic stromal lymphopoietin protein and gene expres
in skin tissue from chronically HCV-infected patients with and w
Category T
Protein
Cryoglobulinemic patients (n = 36) 33 (92)
P <0.0001
Noncryoglobulinemic patients (n = 24) 5 (21)
NS
Healthy controls (n = 10) 0
HCV, hepatitis C virus; NS, not significant; TSLP, thymic stromal lymphopoietin.specimens from CV patients and in none of those from
either the non-CV patients or healthy individuals.
The relationship between TSLP protein, specific mRNA
expression, and the occurrence of HCV core protein or
viral RNA is summarized in Table 2. TSLP protein was up-
regulated and revealed by immunofluorescence in 33 (92%)sion in relation to HCV core protein and HCV RNA detection
ithout cryoglobulinemic vasculitis and from healthy controls
Skin tissue
SLP HCV
mRNA (%) Core protein RNA
36 (100) 29 (81) 2 (6)
P <0.0001
24 (100) 2 (8) 0
NS
10 (100) 0 0
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but in none of the controls (P <0.0001). HCV core protein
was detected in the skin tissue of 29 (81%) CV patients and
two (8%) non-CV patients (P <0.0001). Conversely, all of
the skin biopsies from healthy subjects tested negative for
the immune detection of both TSLP protein and HCV core
protein.
Thymic stromal lymphopoietin gene quantitation in liver
and skin compartments
Potential differences in TSLP gene regulation between
specific biologic compartments were searched for by
measuring mRNA expression levels in the skin and in
the corresponding liver tissue samples of CV and non-
CV patients (Figure 3). A median of 434 (range, 10 to
1,026) mRNA copies/ng total RNA was estimated in the
skin and 3.4 (range, 2.1 to 74) mRNA copies/ng total
RNA in the liver samples (P <0.0001) of CV patients. In
sharp contrast, TSLP gene expression was significantly
downregulated in the skin compared with the liver in
non-CV patients, with a median of 0.29 (range, 0.13 to
22.2) mRNA copies/ng total RNA and 3.3 (range, 0.75 to
28.4) mRNA copies/ng total RNA (P <0.0001), respect-
ively. TSLP gene expression was thus strikingly differentFigure 3 Thymic stromal lymphopoietin gene expression measureme
of cryoglobulinemic vasculitis (CV) and non-CV patients. TSLP, thymic stromin the skin from CV patients compared with that from
non-CV patients (P <0.0001).
Serum TSLP soluble protein
Basal serum levels of TSLP protein were measured in all
HCV-positive CV and non-CV patients and in all healthy
subjects. At the time of serum TSLP measurement, none of
the HCV-infected patients was receiving specific antiviral
treatment and/or immunosuppressive drugs. TSLP levels
were significantly higher in CV patients (median, 186 pg/
ml; range, 97 to 435) than in either non-CV patients (me-
dian, 70.7 pg/ml; range, 16 to 157) or healthy subjects (me-
dian, 0 pg/ml; range, 0 to 18) (P <0.0001 in both cases).
Spearman’s rank correlation test was used to assess the
strength of the association between basal TSLP concentra-
tions and virologic and laboratory parameters (Table 3). A
positive correlation was found with serum HCV nonenve-
loped core protein (P = 0.02), C1q (P = 0.003), C3 (P =
0.0001), and number of peripheral CD20+ cells (P = 0.0009).
On the contrary, there was no relationship with mean
age of the patients, circulating HCV RNA or cryopro-
tein levels, rheumatoid factor, serum concentrations of
IgM and C4 complement component, and alanine
aminotransferase activity.nt. Absolute quantitative real-time RT-PCR in the skin and liver tissues
al lymphopoietin.
Table 3 Spearman’s rank correlation analysis of serum thymic stromal lymphopoietin levels versus laboratory/clinical
parameters in 36 patients with HCV-related cryoglobulinemic vasculitis
Parameter r coefficient 95% confidence interval P valuea
Epidemiology
Age (years) −0.2144 −0.5147 to 0.1328 0.2092
Virology
Serum HCV RNA (log IU/ml) −0.2000 −0.5307 to 0.1836 0.2893
Serum HCV nonenveloped core protein (pg/ml) 0.4182 0.0768 to 0.6718 0.02
Laboratory
Cryocrit (%) −0.0845 −0.4104 to 0.2605 0.6241
Rheumatoid factor (IU/ml) −0.1182 −0.4520 to 0.2447 0.5125
IgM (mg/dl) 0.1000 −0.2619 to 0.4373 0.5798
C1q (mg/dl) 0.6571 0.2605 to 0.8640 0.0030
C3 (mg/dl) 0.7335 0.5137 to 0.8629 0.0001
C4 (mg/dl) 0.1388 −0.2085 to 0.4551 0.4194
ALT (IU/l) 0.1763 −0.2072 to 0.5129 0.3514
Peripheral CD20+ cells (%) 0.7143 0.3581 to 0.8890 0.0009
HCV, hepatitis C virus. aP <0.05 was defined as significant.
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Changes in the serum TSLP levels were investigated fol-
lowing therapy in all CV patients. Baseline serum levels
of this cytokine were slightly but not significantly lower
in 16 responder patients (44.4%) compared with 20
nonresponder patients (55.6%). In the first group, the
administration of pIFNα/RBV combination therapy re-
sulted in a dramatic improvement of cryoglobulin-
related signs and symptoms, a remarkable decrement of
the cryocrit, and the disappearance of serum HCV RNA.
This complete response was found to be associated with
a significant drop in TSLP serum levels (Figure 4). In
sharp contrast, TSLP levels remained roughly unchanged
in the group of unresponsive patients.
Discussion
The main features of this study can be summarized as
follows: untreated patients with HCV-related CV exhibit
a significant median increase in the TSLP mRNA tran-
scripts of skin mRNA tissue samples compared with the
corresponding liver samples; basal and suprabasal kerati-
nocytes and hepatocytes have been identified as the
sources of TSLP; serum TSLP protein levels are signifi-
cantly higher in CV patients than in either non-CV pa-
tients or healthy subjects; higher serum levels of TSLP
in CV patients are associated with a higher frequency of cir-
culating monoclonal/oligoclonal expansions of B cells in
the large majority of these patients; and achievement of
complete response by the combined pIFNα/RBV therapy
results in a highly significant reduction of serum TSLP.
One obvious question stemming from our study is
whether the correlations reported above indeed reflect a
specific mechanistic role of TSLP in the onset of CV orare simply the result of generalized immune activation
in this condition. Several observations, however, argue
against a simplistic interpretation. We have already men-
tioned in the Introduction that TSLP transgenic mice
often develop mixed cryoglobulins and cryoglobulinemic
type I membrano-proliferative glomerulonephritis as
well as additional features that closely resemble import-
ant aspects of the human disease [7]. In addition, a
growing number of studies, highlighted in two recent re-
views [20,21], have provided insightful advances into
TSLP’s pleomorphic roles in diverse disease conditions,
including allergy, autoimmunity, and cancer, thus mak-
ing it unlikely that the elevated TSLP levels are the con-
sequence of rather than the driver of CV.
The changes within the skin microenvironment that
induce TSLP gene expression and the upregulation of
TSLP protein are as yet unclear, given that in the kerati-
nocytes of HCV-infected non-CV patients TSLP gene
expression was downregulated and TSLP protein pro-
duction was absent. It seems unlikely that the upregula-
tion of TSLP in the skin of CV patients is directly
dependent on HCV, in that we have never been able to
convincingly demonstrate HCV RNA amplicons in skin
tissue samples and have no evidence of a direct relation-
ship between HCV RNA levels and the type of and/or
the extent of skin damage.
By analogy with the results obtained in vitro by Lee
and colleagues [14], we have shown in vivo that chronic
HCV infection is able to induce TSLP gene expression
and the hepatocyte production of the protein, which is
then released in the circulation. In addition, circulating
cold-precipitable immune complexes are crucial to the
pathogenesis of cryoglobulin-related cutaneous vasculitis
Figure 4 Serum levels of soluble thymic stromal lymphopoietin protein in cryoglobulinemic vasculitis patients responsive and
unresponsive to antiviral therapy. TSLP, thymic stromal lymphopoietin.
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way, with subsequent damage to endothelial cells and the
initiation of a local inflammatory response [12,22].
TSLP protein was highly expressed in skin biopsies
from CV patients, forming large deposits in dermal ves-
sel walls, a finding reminiscent of the TSLP deposits in
the skin of patients with diffuse cutaneous systemic
sclerosis [23]. It can be assumed that HCV core protein
affects the pathobiology of T-cell responses by inducing
anergy-related genes [24] and in loco generation of a T-
helper 17 response [25]. This raises the intriguing possi-
bility of a cross-talk between hepatocyte-derived TSLP
and skin tissue damage, resulting in the polarization of
DCs and CD4+ T-cell differentiation [1].
In response to pathogens, DCs both produce and re-
spond to TSLP, thereby creating a potential autocrine
loop [26]. According to this view, DCs can be instructed
by TSLP produced in inflamed tissues to migrate into
the interstitial environment of peripheral tissues and to
initiate a suitable immune response [27]. Notably, be-
cause of the critical role of nuclear factor-κB down-
stream of the toll-like receptor signaling pathway, it is
not surprising that toll-like receptor agonists as well asinfectious agents are effective inducers of TSLP expres-
sion in epithelial cells [28].
Although TSLP expression can be induced by the on-
going HCV infection of hepatocytes, we failed to dem-
onstrate a direct relationship between systemic levels of
TSLP and circulating viral RNA. Conversely, serum
TSLP levels correlated well with those of HCV core pro-
tein, indicating an association between higher amounts
of the former and HCV RNA-free structures.
An important point of our study is the detection of a
significant reduction of TSLP serum levels in patients
responsive to pIFNα/RBV combination therapy, probably
reflecting the appropriate blockade of TSLP release by
hepatocytes and keratinocytes. Conversely, the un-
changed levels in unresponsive patients suggest persist-
ing HCV-mediated induction of TSLP production that
contributes to immune system activation. Although the
addition of the anti-CD20 monoclonal antibody rituxi-
mab to the pIFNα/RBV combination has been shown to
result in higher long-term response rates [29], rituximab
alone does not seem to affect the serum TSLP levels: in a
pilot study carried out in nine CV patients different from
those enrolled in this study, no significant variations of
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tion of four weekly intravenous infusions of 375 mg/m2 ri-
tuximab monotherapy (data not shown).
In a proof-of-concept study, the administration of a
fully human anti-TSLP monoclonal antibody G2λ to a
small cohort of patients with stable allergic asthma re-
sulted in a significant attenuation of allergy-induced
early and late asthmatic responses [30]. No therapeutic
proof-of-principle attempts with anti-TSLP monoclonal
antibodies have so far been reported in CV patients, but
it seems reasonable to hypothesize that TSLP blockade
is a potential, targeted therapeutic strategy that could be
added to the current therapies of CV [31].Conclusions
This study points out a novel biological role for TSLP.
Cutaneous expression of TSLP by the keratinocytes of
patients with HCV-related CV may be pivotal in per-
petuating the activation of tissue-resident immunocytes
and in attracting inflammatory cells, thus creating an en-
vironment favorable to the onset of vasculitis. The local
production of TSLP by hepatocytes as well as keratino-
cytes causes a significant increase in its systemic concen-
trations, a step sufficient to promote a break in B-cell
homeostasis and likely to induce B-lineage-dependent
autoimmunity.
Further studies are necessary to evaluate the molecular
basis underlying TSLP upregulation and B-cell derange-
ment in patients with HCV-related CV. Although a dee-
per comprehension of cell-specific signaling pathways
awaits to be defined, given that TSLP has been found
capable of directly acting on CD4+ T cells and of pro-
moting proliferation and T-helper 2 differentiation of
naïve CD4+ T cells through the induction of interleukin-
4 [20], it seems reasonable to hypothesize that the over-
expression of mRNA TSLP in the skin of CV patients
and the consequent cytokine milieu play an important
role in the inflammatory responses that characterize this
peculiar type of HCV-induced vasculitis.Abbreviations
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